VEN is a CYP3A4 inhibitor that significantly interacts with azole antifungal drugs and requires dose adjustment.[23] Antimicrobial prophylaxis is recommended during AML treatment to reduce the infection risk, including invasive fungal infections (IFIs).[24] In this study, 30% of the patients received prophylactic antifungal therapy. The gene discussed is CYP3A4; the disease is acute myeloid leukemia.